|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200056940 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-07 11:43:12 |
|
注册时间: Date of Registration: |
2022-02-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
炎症性肠病合并肌肉衰减症患者营养风险与营养不良观察性研究 |
|
Public title: |
nutrition risk and malnutrition in patients with inflammatory bowel disease combine sarcopenia:a observational study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
炎症性肠病合并肌肉衰减症患者营养风险与营养不良观察性研究 |
|
Scientific title: |
nutrition risk and malnutrition in patients with inflammatory bowel disease combine sarcopenia:a observational study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴优 |
研究负责人: |
汪敏 |
|
Applicant: |
you wu |
Study leader: |
min wang |
|
申请注册联系人电话: Applicant telephone: |
13056420330 |
研究负责人电话:
Study leader's |
18716135801 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2512274551@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
wangmin1605@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省泸州市西南医科大学附属医院 |
研究负责人通讯地址: |
四川省泸州市西南医科大学附属医院 |
|
Applicant address: |
The Affiliated Hospital of Southwest Medical University,sichuan provience luzhou |
Study leader's address: |
The Affiliated Hospital of Southwest Medical University,sichuan provience luzhou |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
西南医科大学附属医院 |
||
|
Applicant's institution: |
The Affiliated Hospital of Southwest Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2022039 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
西南医科大学附属医院临床试验伦理委员会 |
||
|
Name of the ethic committee: |
The Affiliated Hospital of Southwest Medical University clinical trial ethic committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-01-20 00:00:00 | ||
|
伦理委员会联系人: |
张增瑞 |
||
|
Contact Name of the ethic committee: |
zhang zengrui |
||
|
伦理委员会联系地址: |
四川省泸州市太平街25号 |
||
|
Contact Address of the ethic committee: |
25 Taiping Street, Jiangyang District, Luzhou City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
西南医科大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Southwest Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省泸州市江阳区太平街25号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
25 Taiping Street, Jiangyang District, Luzhou City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
西南医科大学附属医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Affiliated Hospital of Southwest Medical University |
||||||||||||||||||||||
|
研究疾病: |
炎症性肠病 |
||||||||||||||||||||||
|
Target disease: |
inflammatory bowel disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1、评估IBD合并肌肉衰减症患者的营养风险和营养水平。 2、比较UC和CD患者肌肉衰减症的患病率。 3、对比分析CT和BIA对IBD合并肌肉衰减症患者的诊断一致性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Assess the nutritional risk and nutritional level of patients with IBD combined with sarcopenia. 2. Compare the prevalence of sarcopenia in patients with UC and CD. 3. Comparative analysis of the consistency of CT and BIA in the diagnosis of patients with IBD and sarcopenia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)有入院前后两周内的腹部CT检查图像;2)年龄不限,明确诊断为炎症性肠病。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) There are CT images of the abdomen within two weeks before and after admission; 2) No age limit, a clear diagnosis of inflammatory bowel disease. |
||||||||||||||||||||||
|
排除标准: |
1)缺失身高、体重等信息;2)合并糖尿病、甲状腺 功能亢进、HIV或恶性肿瘤等疾病;3)伴肢体活动障碍者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Missing information such as height and weight; 2) Complicated with diseases such as diabetes, hyperthyroidism, HIV or malignant tumors; 3) Complicated with physical disorders. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-03-20 00:00:00至 To 2022-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-20 00:00:00 至 To 2022-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无随机化 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
no |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023-06 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
纸质数据 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |